论文部分内容阅读
目的观察来得时联合瑞格列奈治疗2型糖尿病的疗效及安全性分析。方法选择98例经口服药治疗失效的2型糖尿病患者,随机分为两组,对照和观察组均49例,两组均停止服用之前的降糖药物。对照组给予重组人胰岛素(30/70)注射液治疗;观察组给予瑞格列奈片联合来得时治疗,两组均治疗12周。结果两组治疗后与治疗前在FBG、2hPG、HbA1C组内比较,均有明显下降(P<0.01),治疗后两组在FBG组间比较(P>0.05),两组无明显差异,治疗后两组组间在2hPG、HbA1C比较,观察组明显优于对照组(P<0.05或P<0.01);治疗后两组在低血糖发生率相比较(P<0.05),观察组低血糖发生率明显低于对照组。结论来得时联合瑞格列奈治疗2型糖尿病疗效确切,低血糖发生率低,安全性高。
Objective To observe the efficacy and safety of propofol combined with repaglinide in the treatment of type 2 diabetes mellitus. Methods A total of 98 patients with type 2 diabetes mellitus who failed oral administration were randomly divided into two groups. The control and observation groups were given 49 cases of hypoglycemic agents. The control group was treated with recombinant human insulin (30/70) injection. The observation group was treated with repaglinide for the time being. The two groups were treated for 12 weeks. Results The levels of FBG, 2hPG and HbA1C before and after treatment in both groups were significantly decreased (P <0.01). After treatment, there was no significant difference between the two groups in the FBG group (P> 0.05) After 2hPG and HbA1C, the observation group was better than the control group (P <0.05 or P <0.01), the incidence of hypoglycemia in the two groups after treatment was significantly higher than that in the control group (P <0.05) The rate was significantly lower than the control group. Conclusions The combination of repaglinide with type 2 diabetes mellitus has a definite effect, low incidence of hypoglycemia and high safety.